Revenues for the quarter ended Sept. 30 totaled $11 million, down from $16 million during the same period last year.
R&D expenses declined to $4.7 million from $5.4 million during the year-ago quarter.
Ciphergen's loss for the quarter widened to $9.5 million, or $.33 per share, almost twice as much as last year's loss of $5.2 million, or $.18 per share, during the third quarter.
As of Sept. 30, Ciphergen had $19 million in cash, cash equivalents, and investments in securities.
Last week, the company said it will sell its BioSepra business to Pall for $32 million.